Abstract
Symmetrical N,N'-diarylureas: 1,3-bis(3,4-dichlorophenyl)-,1,3-bis[4-chloro-3-(trifluoromethyl)phenyl]- and 1,3-bis[3,5-bis(trifluoromethyl)phenyl]urea, were identified as potent activators of the eIF2a kinase heme regulated inhibitor. They reduce the abundance of the eIF2.GTP.tRNAiMet ternary complex and inhibit cancer cell proliferation. An optimization process was undertaken to improve their solubility while preserving their biological activity. Non-symmetrical hybrid ureas were generated by combining one of the hydrophobic phenyl moieties present in the symmetrical ureas with the polar 3-hydroxy-tolyl moiety. O-alkylation of the later added potentially solubilizing charge bearing groups. The new non-symmetrical N,N'-diarylureas were characterized by ternary complex reporter gene and cell proliferation assays, demonstrating good bioactivities. A representative sample of these compounds potently induced phosphorylation of eIF2a and expression of CHOP at the protein and mRNA levels. These inhibitors oftranslation initiation may become leads for the development of potent, non-toxic, and target specific anti-cancer agents.